share_log

Why Moderna Shares Are Falling

Why Moderna Shares Are Falling

為什麼摩登那的股價在下跌？
Benzinga Real-time News ·  2021/09/27 14:18

Shares of COVID-19 vaccine makers, including Moderna Inc (NASDAQ:MRNA), are trading lower amid continued volatility in the space as investors weigh booster shot progress. Pfizer CEO Albert Bourla recently predicted a return to 'normal life' within a year with a likely need for annual shots.

新冠肺炎疫苗製造商的股票，包括Moderna(納斯達克股票代碼：mRNA)，由於投資者權衡提振進展，該領域持續波動，股價走低。輝瑞(Pfizer)首席執行官阿爾伯特·布拉(Albert Bourla)最近預測，一年內將恢復“正常生活”，可能需要每年注射一次。

Shares of companies in growth sectors are also trading lower amid a rise in the 10-year treasury yield. The 10-year Treasury yield hit an intraday high of 1.517% Monday morning before dipping to around the 1.484% level. The move in the 10-year note comes after the Federal Reserve last week spoke on winding down its ongoing asset purchasing program.

隨着10年期美國國債收益率上升，成長型行業公司的股價也在走低。10年期美國國債收益率週一早盤觸及1.517%的盤中高點，之後回落至1.484%左右。在10年期公債走勢之前，美聯儲(Federal Reserve)上週就逐步結束正在進行的資產購買計劃發表了講話。

Moderna is commercial-stage biotech that was founded in 2010. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020.

現代生物技術公司成立於2010年，是一家處於商業階段的生物技術公司。該公司的信使核糖核酸技術迅速通過了其新冠肺炎疫苗的驗證，該疫苗於2020年12月在美國獲得授權。

Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease and rare genetic diseases.

截至2021年初，現代有24個mRNA開發項目，其中13個正在進行臨牀試驗。項目涵蓋廣泛的治療領域，包括傳染病、腫瘤學、心血管疾病和罕見的遺傳病。

Moderna has a 52-week high of $497.49 and a 52-week low of $65.49.

摩德納的52周高點為497.49美元，52周低點為65.49美元。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論